Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Judith Trotman

Showing results (61-70 of 148) with videos related to

Pageof 15
Sort By:
Blood|March 22, 2018
Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL studyAnne Ségolène Cottereau, Annibale Versari, Stefano Luminari, et al.
British Journal of Clinical Pharmacology|June 25, 2010
Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapyChrista E Nath, Peter J Shaw, Judith Trotman, et al.
The Lancet. Oncology|October 13, 2018
Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trialJudith Trotman, Sally F Barrington, David Belada, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2016
Reply to H.J.A. Adams et al and E. Laffon et alMichel Meignan, Anne Ségolène Cottereau, Annibale Versari, et al.
Ejhaem|November 29, 2023
A comparison of the prognostic performance of the Lugano 2014 and RECIL 2017 response criteria in patients with NHL from the phase III GOYA and GALLIUM trialsLale Kostakoglu, Maurizio Martelli, Laurie H Sehn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2021
Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate<sup>TM</sup> TrialJudith Trotman, Christian Buske, Alessandra Tedeschi, et al.
JCO Clinical Cancer Informatics|February 22, 2020
CART-WHEEL.org: An Ethically Approved Online Database for Patient-Entered Data to Facilitate Rare Cancer ResearchDamien Kee, Clare Parker, Susie Bae, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2016
Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter StudiesMichel Meignan, Anne Ségolène Cottereau, Annibale Versari, et al.
British Journal of Haematology|December 16, 2021
Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 studyGavin Cull, Jan A Burger, Stephen Opat, et al.
The Lancet. Haematology|April 1, 2016
Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studiesJudith Trotman, Stefano Luminari, Sami Boussetta, et al.
Pageof 15

Showing results (61-70 of 148) with videos related to

Sort By:
Pageof 15
Blood|March 22, 2018
Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL studyAnne Ségolène Cottereau, Annibale Versari, Stefano Luminari, et al.
British Journal of Clinical Pharmacology|June 25, 2010
Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapyChrista E Nath, Peter J Shaw, Judith Trotman, et al.
The Lancet. Oncology|October 13, 2018
Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trialJudith Trotman, Sally F Barrington, David Belada, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2016
Reply to H.J.A. Adams et al and E. Laffon et alMichel Meignan, Anne Ségolène Cottereau, Annibale Versari, et al.
Ejhaem|November 29, 2023
A comparison of the prognostic performance of the Lugano 2014 and RECIL 2017 response criteria in patients with NHL from the phase III GOYA and GALLIUM trialsLale Kostakoglu, Maurizio Martelli, Laurie H Sehn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2021
Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate<sup>TM</sup> TrialJudith Trotman, Christian Buske, Alessandra Tedeschi, et al.
JCO Clinical Cancer Informatics|February 22, 2020
CART-WHEEL.org: An Ethically Approved Online Database for Patient-Entered Data to Facilitate Rare Cancer ResearchDamien Kee, Clare Parker, Susie Bae, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2016
Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter StudiesMichel Meignan, Anne Ségolène Cottereau, Annibale Versari, et al.
British Journal of Haematology|December 16, 2021
Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 studyGavin Cull, Jan A Burger, Stephen Opat, et al.
The Lancet. Haematology|April 1, 2016
Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studiesJudith Trotman, Stefano Luminari, Sami Boussetta, et al.
Pageof 15